PORTFOLIO 14MG 14M Genomics was a cancer diagnostic business that was founded in partnership with the Wellcome Trust Sanger Institute in 2014. Syncona committed a Series A financing of £12million investing £5.5m to test our investment thesis with milestones for the drawdown of the next tranche of funding that were explicitly designed to test the core investment thesis. The company progressed pre-clinical studies, however, a careful review of the data generated from these studies, did not did not support further investment. We worked collaboratively with the management team to close the business, supporting the team who worked at the company and recovered £0.5m of our investment. Other previous investments portfolio companies Other domain areas Cell therapy Gene therapy Biologics Small molecule Sign-up for company news alerts Get the latest RNS, company news, share price information and results from Syncona RNS ALERTS COMPANY ALERTS Contact Syncona Investment Management Limited 2nd Floor 8 Bloomsbury Street London WC1B 3SR contact@synconaltd.com Explore About us Our people Portfolio Sustainability News and Insights Investors Contact Copyright © Syncona 2021 Accessibility Privacy & cookies Employee privacy notice Third party privacy notice Regulatory publications Modern Slavery Statement Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD. Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited. Designed & built by SampsonMay Accept to continue or find out more in our cookie policy. Change settings ACCEPT AND CLOSE